LLY compared with MNPR: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

MNPRMonopar Therapeutics

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

MNPRMonopar Therapeutics

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

MNPR

Reportimpliedrealized× implied

Q2 FY26—▲+0.38%—

May 14 '26—▼−0.73%—

Q1 FY26

= impliedLLY realized, solidMNPR realized, hatchedOne scale, both sides: full bar = 11%× = |realized| ÷ impliedSource: market data

—

▼−0.84%

—

Q3 FY25—▲+5.36%—

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

MNPRMonopar Therapeutics

71.11▲+5.79%· post 71.11

ClosedNov 6 '26

Mkt cap$451.2MRevenue—Revenue—

Compare

ClosedNov 6 '26

LLYELI Lilly & Co

MNPRMonopar Therapeutics

1,360.90▼−0.28%post 1,358.90

Price

71.11▲+5.79%post 71.11

$1.2T

Mkt cap

$451.2M

Q3 FY26$24.4B

Revenue

—

FY25$65.2B

Revenue

—

LLY1,360.90▼−0.28%vsMNPR71.11▲+5.79%ClosedNov 6 '26